Arca
Skip to content
Tools
Tools

TNFRSF13C: Tumor necrosis factor receptor superfamily member 13C

B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on TNFRSF13C, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved0

    Phase 31

    • Ianalumab

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        IanalumabPhase 3Novartis PharmaceuticalsAntibodyBinding agentTumor necrosis factor receptor superfamily member 13C binding agent16

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.IanalumabPhase 2Not yet recruitingNovartis PharmaceuticalsJun 22, 2026
        Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenIanalumabPhase 3RecruitingNovartis PharmaceuticalsJun 2, 2026
        A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)IanalumabPhase 2RecruitingNovartis PharmaceuticalsFeb 19, 2026
        Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)IanalumabPhase 3RecruitingNovartis PharmaceuticalsDec 2, 2024
        A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisIanalumabPhase 2Active, not recruitingNovartis PharmaceuticalsJun 24, 2024
        Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseIanalumabPhase 2Active, not recruitingNovartis PharmaceuticalsMar 5, 2024
        Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).IanalumabPhase 3RecruitingNovartis PharmaceuticalsNov 18, 2023
        A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.IanalumabPhase 3Active, not recruitingNovartis PharmaceuticalsAug 14, 2023

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Immunodeficiency, common variable, 40.63
        • Common variable immunodeficiency0.44
        • Recurrent infections associated with rare immunoglobulin isotypes deficiency0.42
        • Sjogren syndrome0.37
        • Autoimmune thrombocytopenic purpura0.35
        • Immunodeficiency, common variable, 20.12

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630882, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q96RJ3, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.